

Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress

Ashvini Keshavan¹ · Amanda Heslegrave² · Henrik Zetterberg^{2,3,4} · Jonathan M. Schott¹

Published online: 13 October 2016
© Springer International Publishing Switzerland 2016

Abstract Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis, predict disease progression, stratify individuals and track response to candidate therapies in drug trials. The first fluid biomarkers reflecting aspects of AD neuropathology were identified in cerebrospinal fluid (CSF) in the 1990s. Three CSF biomarkers (amyloid- β 1–42, total tau and phospho-tau) have consistently been shown to have diagnostic utility and are incorporated into the new diagnostic criteria for AD. These markers have also been shown in longitudinal studies to predict conversion of mild cognitive impairment to AD. However, a key issue with the use of CSF biomarkers as a screening test is the invasiveness of lumbar puncture. Over the last 20 years there has been an active quest for blood biomarkers, which could be easily acquired and tested repeatedly throughout the disease course. One approach to identifying such markers is to attempt to measure candidates that have already been identified in CSF. Until recently, this approach has been limited by

assay sensitivity, but newer platforms now allow single molecule-level detection. Another approach is identification of candidates in large multiplex panels that allow for multiple analytes to be quantified in parallel. While both approaches show promise, to date no blood-based biomarker or combination of biomarkers has sufficient predictive value to have utility in clinical practice. In this review, an overview of promising blood protein candidates is provided, and the challenges of validating and converting these into practicable tests are discussed.

Key Points

Many studies have identified candidates for blood biomarkers of Alzheimer's disease (AD) but replication has been problematic.

The two main candidates showing promise currently are plasma total tau and serum neurofilament light chain.

New techniques such as multiplexing and use of more sensitive assays are likely to expand and improve blood biomarker research.

H. Zetterberg and J. M. Schott are joint senior author of this article.

✉ Jonathan M. Schott
j.schott@ucl.ac.uk

¹ Dementia Research Centre, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Box 16, Queen Square, London WC1N 3BG, UK

² Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

³ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden

⁴ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

1 Introduction

The neuropathological signature of Alzheimer's disease (AD) is neuronal loss with deposition of amyloid- β (A β) in extracellular plaques and accumulation of hyper-phosphorylated tau protein in intracellular neurofibrillary tangles.

Extrapolation from post-mortem studies suggests that in most cases these proteins propagate through the brain in a reliable progression, which is reflected in neuropathological staging systems for AD [1]. These studies showed that early stage AD neuropathology exists in individuals who are asymptomatic, paving the way for pre-symptomatic diagnosis and clinical trials aiming to prevent cognitive decline. Given the obvious limitations of obtaining brain tissue during life, there has been considerable interest in discovering disease-specific biomarkers both in the symptomatic and pre-symptomatic phases.

Ideal biomarkers have different characteristics based on the information they aim to give [1]. For example, an ideal diagnostic biomarker would reliably reflect *in vivo* pathology with high sensitivity and specificity. A screening biomarker would combine at least moderate sensitivity with high specificity and low cost. Conversely, a marker of progression may be downstream of the initial pathology but reliably track change over time. For all biomarkers, reliability, cost, and ease of acquisition and processing are important considerations.

The currently available biomarkers for AD include structural imaging (e.g. magnetic resonance imaging [MRI] and computed tomography), functional imaging (e.g. 18-fluorodeoxyglucose positron emission tomography [PET]), molecular imaging (e.g. A β and tau PET) and fluid biomarkers (from cerebrospinal fluid [CSF], blood and urine). The focus of this review is fluid biomarkers in AD.

2 Cerebrospinal Fluid Biomarkers: Established and Emerging

Studies have shown that low CSF A β 42 [2], high CSF total tau (t-tau) [3] and high CSF phospho-tau [4] in life are correlated with a clinical diagnosis of AD, and also with severity of AD pathology post-mortem [5, 6]. Moreover, several large multicentre studies have shown this pattern to predict which patients with mild cognitive impairment (MCI) will progress to AD [7–9]. This implies that the change in CSF biomarkers must occur during the preclinical stage of AD. This CSF biomarker signature is now established in both the International Working Group (IWG)-2 and National Institute on Aging (NIA) diagnostic criteria for AD, in pre-symptomatic, prodromal (MCI), typical and atypical forms of AD [3, 10–13].

Newer CSF biomarkers that reflect other aspects of AD remain an active topic of research. The postsynaptic marker neurogranin has been identified in multiple cohorts as being able to differentiate AD from control with an effect size (defined as fold change in the mean biomarker concentration between AD and control groups) of 1.9 in a recent meta-analysis [14], and to differentiate MCI patients

who will progress to AD [effect size 1.5] [15]. Other studies have provided evidence that numerous other CSF markers may be able to distinguish AD from controls, including heart fatty acid binding protein [16], neuron-specific enolase [17], neurofilament light chain (NFL) [18], YKL-40 [19] and visinin-like protein-1 [20], with effect sizes ranging from 1.3 to 2.3. However, none is currently more diagnostically useful than the established markers A β 42 and tau, suggesting that the true utility of these additional markers will come from understanding their relationship to the underlying pathology, and in using them to ask more refined questions. For example, a diagnostic marker is most useful when it can differentiate AD from other dementias. This has been recently observed by Wellington et al. [21] for neurogranin, which rises specifically in AD but not in other diseases such as Lewy body dementia (LBD) and behavioural variant frontotemporal dementia (FTD) which often are in the differential diagnosis of AD. Another more specific function of a diagnostic biomarker would be to differentiate subtypes of AD. Paterson et al. [22] have shown that the latter may be the case for CSF NFL, which is higher in the CSF of patients in the frontal variant subgroup of AD than in other ‘atypical’ variants of AD as defined by the IWG-2 criteria; this represents a group that tends to have younger onset and more aggressive disease.

‘Traditional’ assay development has been on a single candidate molecule approach, devising specific enzyme-linked immunosorbent assays (ELISAs) for proteins thought to be relevant to the disease. This approach has its limitations: it is slow and relies on *a priori* assumptions of the role of the candidate analyte in disease pathogenesis. Thus, many groups have turned to employing multiplexing approaches in CSF [23, 24]. A recent example is Heywood et al.’s mass spectrometry-based targeted proteomics assay in CSF from two independent cohorts [25], which demonstrated 23 proteins (six of which were novel) that differentiate AD and LBD from controls. Four proteins (two of which were novel) differentiated AD from both LBD and controls. Many of these markers did not show a relationship with CSF A β 42, t-tau or phospho-tau, implying that their association with the pathology of AD may be unrelated to amyloid plaques and tau neurofibrillary tangles.

3 Minimally Invasive Tests

While CSF biomarkers have proven utility, obtaining CSF remains a relatively invasive procedure. Lumbar puncture is not without complications (the commonest of which is headache) and it is relatively contraindicated in patients with clotting disorders and those who are taking

anticoagulant medication. It requires a skilled operator and appropriate facilities to take, process and store samples, which are sensitive to handling errors. This set of systems and processes adds to the overall cost of the test. The optimal biomarker(s) would therefore be obtained via a non-invasive, relatively cheap and easily repeatable test. Blood, which is collected paired with CSF in most major fluid biomarker research initiatives, provides this opportunity.

4 Blood Biomarkers

4.1 The Candidate Approach

Identification of peripheral biomarkers reflecting central nervous system (CNS) dysfunction is challenging for many reasons. First, molecules from the brain must cross the blood–brain barrier. Second, their concentration in blood is likely to be much smaller than that in CSF, due to the much higher volume of dilution in blood. Third, the high concentration of plasma proteins can be either a sink for secreted proteins from the brain (due to binding or enzymatic breakdown) or a source of similar or identical proteins. Taking the example of plasma A β 42, many of these factors come into play. A β 42 is present at very low concentrations in plasma, it is prone to plasma protein binding and may be eliminated by enzyme activity. These factors may explain why plasma A β 42 does not correlate well with the CSF profile [26–29] and there are mixed reports of inverse correlation [30] and of lack of correlation [31] of plasma A β 42 with amyloid PET. Further problems with plasma A β 42 are its susceptibility to technical factors such as aliquot volume and delay to freezing samples [32].

To date, only one blood biomarker has been shown to distinguish AD from control subjects across multiple patient populations. Plasma t-tau was shown in a recent meta-analysis across six comparisons [33, 34] to have an effect size of 1.95 (95 % CI 1.12–3.38; $n = 271$ AD, 394 controls). Yet even within this meta-analysis there was significant variation depending on the method used to quantify t-tau. One of these studies showed a significant inverse effect [35] and one showed no appreciable effect [36]—both used conventional ELISA methods that were not optimised to measure the low concentrations of tau in the blood. A more sensitive immunomagnetic reduction method was used in three other comparisons derived from two studies by the same group [37, 38] and showed effect sizes consistent with the results of the overall meta-analysis, but these results, using this particular measurement technique, are in need of independent replication. The final study [39] utilised a single molecular digital array platform that is able to quantify t-tau at the single molecule level and

proved to have the highest sensitivity of the three methods [40]. This study compared AD with MCI and control subjects from a Swedish cohort, showing that while plasma t-tau differentiates AD from control, there is no significant effect for MCI versus control. The former finding has been replicated in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort and the Swedish BioFINDER study [41] and the latter finding has been independently replicated in a larger cohort from the Mayo Clinic Study of Aging [42], using the same platform. While the difference in plasma t-tau levels between MCI and control did not reach statistical significance, there was a significant inverse correlation between plasma tau and cognitive performance (in the global, memory and attention/executive function domains), as well as between plasma t-tau and cortical thickness in an AD region of interest defined on MRI. A summary of the studies published thus far is provided in Table 1.

While plasma tau shows some promise, interpretation of the various studies is not easy, given that plasma t-tau is known to vary widely even in healthy individuals; and tau elevation is not specific to AD, as it is seen in many diseases with rapid neuronal destruction (e.g. prion disease) as well as after traumatic brain injury [43]. There is also a lack of correlation between CSF and plasma t-tau within individuals [36]. Further studies in different cohorts are needed to understand what plasma tau elevation means before it can be more routinely used in research and certainly before any potential clinical translation.

Another recent advance in the blood biomarker domain is the discovery of the relationship between serum NFL and the progression of neurodegenerative diseases. NFL in CSF may discriminate FTD from other types of dementia [44] and be an indicator of disease severity in FTD [45]. More recently, there have been reports of serum NFL also reflecting disease severity in FTD [46, 47] and correlating with the annualised frontal lobe atrophy rate in FTD [47]. In an extensive body of work spanning mouse *APP-PS1* (amyloid precursor protein–presenilin 1) mutant models and human CSF and blood sampling, Bacioglu et al. [48] showed that both CSF and serum NFL are raised in AD compared with control patients. Serum NFL was highest in patients with tauopathies (with effect sizes ~ 3 to 6) and moderately high in those with AD and atypical parkinsonian syndromes (with effect sizes ~ 3), but was no different in those with idiopathic Parkinson's disease compared with controls, lending support to the view that this may be a useful test in distinguishing idiopathic Parkinson's disease from atypical parkinsonism. Serum NFL broadly correlated with CSF within individuals (a finding that has been corroborated by others for both serum [49] and plasma [50]) and also correlated with Mini-Mental State Examination scores. Treatment of the mouse *APP-*

Table 1 Key blood biomarker studies in Alzheimer's disease showing significant results using the candidate approach

Study, year	Assay	Cohort (n)	Summary of results (effect size 95 % CI)
Total plasma tau			
Sparks et al. 2012 [35]	ELISA	AD (49) Control (110)	Tau lower in AD
Chiu et al. 2013 [37]	Immunomagnetic reduction	2 AD groups (31 + 30) Control (107)	Tau higher in AD
Chiu et al. 2014 [38]	Immunomagnetic reduction	AD (10) Control (30)	Tau higher in AD
Zetterberg et al. 2013 [39]	Single molecular digital immunoarray	AD (54) Control (25)	Tau higher in AD
Dage et al. 2016 [42]	Single molecular digital immunoarray	MCSA cohort: MCI (161) Control (378)	Tau in MCI was not statistically significantly higher than in controls but after adjustment for age, sex, education and APOE genotype, higher tau was associated with: 1. Worse performance in tests of global cognition, memory and attention; and 2. Reduced cortical thickness in an AD signature region on MRI
NFL, serum			
Bacioglu et al. 2016 [48]	ELISA adapted to electrochemiluminescent platform	Control (35) MCI (33) AD (34) IPD (32) DLB (20) MSA (17) PSP (24) CBS (10)	Serum NFL higher in AD (effect size ~3) but not statistically significant for MCI Significant correlation between cognitive performance on MMSE and CSF NFL or serum NFL in AD

AD Alzheimer's disease, CBS corticobasal syndrome, CI confidence interval, CSF cerebrospinal fluid, DLB dementia with Lewy bodies, ELISA enzyme-linked immunosorbent assay, IPD idiopathic Parkinson's disease, MCI mild cognitive impairment, MCSA Mayo Clinic Study of Aging, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, MSA multisystem atrophy, NFL neurofilament light chain, PSP progressive supranuclear palsy

PSI models with a β -secretase-1 inhibitor, which reduces the generation of A β 42 and the formation of amyloid plaques, led to a reduction in both CSF and plasma NFL, which was not observed in the untreated *APP-PSI* mice. Taken together, these findings raise the prospect of using blood NFL as a possible treatment response biomarker in AD trials, as, unlike plasma t-tau, serum NFL seems to track the CSF levels and the progression of disease. Notably, a statistically significant elevation in serum NFL was not seen in MCI, but this may yet change as serum NFL is measured in pre-symptomatic and mildly symptomatic subjects (such as in the Dominantly Inherited Alzheimer's Network cohort) with higher sensitivity assays such as single molecular array. It will be interesting in such cohorts to determine whether models that combine serum NFL levels with serial MRI data could provide more predictive value for disease severity than using either test alone.

Any such efforts will need to adopt a standardised approach across centres to allow for cross-validation, and

there is now an international working group pre-analytic processing guideline [51], which will continue to evolve as additional research findings become available. The guideline refers to "controllable" and "uncontrollable" variables. These match technical variables (in blood collection/handling/storage) and patient factors (such as demographics, genotype, co-morbidities and lifestyle factors), respectively. While the former should be standardised, collecting information on the latter will allow for stratification and interesting between-group comparisons that may ultimately inform the application of a particular biomarker as a screening, diagnostic, prognostic or therapeutic indicator.

4.2 Multiplexing

As has occurred in the CSF field, multiplexing approaches to plasma proteomics have been employed by several investigators in an effort to define groups of proteins that may inform pathways to the development and progression

Table 2 Key blood biomarker studies in Alzheimer's disease showing significant results using the multiplexing approach. This represents a non-exhaustive list of relevant studies

Study, year	Assay	Cohort (n)	Markers	Summary of results
Zhang et al. 2004 [57]	LC + SDS-PAGE + MS Cross-validation with WB and ELISA	AD (41) Control (30) Study also included sera from patients with insulin-resistant diabetes mellitus and congestive heart failure patients	In serum: 12 proteins elevated in AD; 1 protein reduced in AD	3 proteins (APOE, transthyretin and histidine-rich glycoprotein) show specific elevations in AD but not in other disease sera 1 protein shows specific reduction in AD: α -1 acid glycoprotein No statements of diagnostic accuracy, sensitivity or specificity
Lopez et al. 2005 [60]	AC + MS	AD (62) MCI (33) Control (207)	In serum: 2 models generated by peptide spectral signatures	Sensitivity 83 % and specificity 90–96% achieved by the 2 models; contribution of individual peptides not analysed
Ray et al. 2007 [52]	Cytokine antibody microarray; sandwich ELISA	AD (85) MCI (47) Other dementia (11) Other neurological disease (22) Rheumatoid arthritis (16) Control (79)	In plasma: 120 cell signalling proteins probed; 18 proteins identified	91 % accuracy in predicting MCI converting to AD, 100 % accuracy in predicting MCI converting to non-AD dementia
Soares et al. 2009 [53]	Sandwich ELISA	ADNI cohort: AD (61) Control (952)	In serum: 151 protein panel, including 8 proteins from Ray et al. [52]	61 % accuracy in classifying AD vs. control; unable to replicate results of Ray et al. [52]
Doecke et al. 2012 [56]	Multiple methods, including: multiplexed immunoassay platform for a 151 protein panel ELISA for A β 40 and A β 42 MS for metal ions and protein panel genotyping for APOE statistical methods for generating a predictive model based on age, sex, education level and APOE genotype	AIBL cohort: AD (207) Control (754) ADNI cohort: AD (112) Control (58)	In plasma: 151 analytes probed: 138 proteins associated with AD of these, 8 markers were chosen: cortisol, IGFBP2, PPY, IL-17, VCAMI, VCAM2 β -2 microglobulin EGFR and CEA	IGFBP2 and PPY each had individual effect sizes >1.5; these and several other markers had been replicated in other studies The 8 most predictive markers, which were flagged by each of four statistical methods, were able to increase the sensitivity and specificity of the predictive model based on age, sex, education and APOE genotype from 77 to 83 %

Table 2 continued

Study, year	Assay	Cohort (n)	Markers	Summary of results
Hu et al. 2012 [62]	Multiplexed immunoassay platform for a 190 protein panel <i>APOE</i> genotyping	Penn cohort: Control (126) MCI (16) AD (88) Other dementias (37) WU cohort: Control (242) CDR 0.5 or very mild dementia (63) CDR 1.0 or mild dementia (28) ADNI cohort (both clinical diagnoses and CSF-driven diagnoses available): Control (58) MCI (396) AD (112)	In plasma in Penn and WU cohorts: 17 candidate proteins identified in univariate analysis across both cohorts to be associated with clinical MCI/AD; 5 replicated by another study in serum 6 of these survived multivariate analysis and correction for age and sex In fasting plasma in ADNI: 6 candidates were identified by univariate analysis 4 of these showed correlations with disease status defined by CSF 2 of these survived multivariate analysis and correction for age and sex	6 markers were common to both testing cohorts for MCI/mild dementia/AD: α -1-antitrypsin, APOE, CRP, N-terminal pro B-type natriuretic peptide, osteopontin and serum amyloid P. Individual effect sizes ranged from 0.8 to 1.1. In the ADNI validation cohort, when disease status was defined by a CSF signature of CSF A β 42 levels <193 pg/mL and a CSF t-tau/A β 42 ratio >0.39, 4 markers were identified: APOE, BNP, CRP, and pancreatic polypeptide. The latter 3 were independent of cholinesterase inhibitor use. BNP and pancreatic polypeptide showed significant linear correlation with the <i>APOE4</i> allele number and the CSF A β 42 level; pancreatic polypeptide also showed significant linear correlation with the CSF t-tau/A β 42 ratio. APOE, BNP and CRP were therefore common to all 3 cohorts. The main limitations of the study included: 1. methodological differences across the three cohorts in the sample collection (fasting vs. non-fasting) 2. the grouping of MCI/mild dementia/AD vs. controls in the analysis, resulting in an inability to comment on the correlation between these markers and disease severity 3. small individual effect sizes and low contribution of the plasma biomarkers to explaining the variance in the CSF markers in the ADNI cohort
Björkqvist et al. 2012 [54]	Quantitative multiplex ELISA electrochemiluminescence multiarray	AD (142) Control (174) Other dementias (88)	In plasma: EGF, PDGF-BB and MIP-1 δ	3 markers able to distinguish AD from control but not from other dementias; diagnostic precision 63 %
Trushina et al. 2013 [58]	LC + MS	AD (15) MCI (15) Control (15)	342 plasma and 351 CSF metabolites altered in AD	23 altered canonical pathways in plasma and 20 in CSF in MCI vs. control with a false discovery rate of <5 %
Sattler et al. 2014 [59]	Aptamer-based microarray	AD (331) MCI (106) Control (211) 43 MCI patients converted to AD within a year	In plasma: total of 355 proteins associated with at least 1 of the outcome measures; 13-member panel selected 20 proteins associated with conversion of MCI to AD but none passed multiple testing corrections	Biomarker profiles correlated with different outcome measures, including: region-specific atrophy on MRI (e.g. pancreatic prohormone correlated with left hippocampal volume) rate of cognitive decline (e.g. clusterin) 13 protein panel showed sensitivity 67 %, specificity 64 %, positive predictive value 70 %

Table 2 continued

Study, year	Assay	Cohort (n)	Markers	Summary of results
Mapstone et al. 2014 [63]	LC + MS	Untargeted screen: Control elderly (53) MCI/mild AD (53, including 18 converters over 2 years) Targeted panel (separate cohort): Normal elderly (20) MCI/mild AD (21, including 10 converters over 2 years)	In fasting plasma: 10 plasma lipids	10 lipid panel able to distinguish converters from normal controls with diagnostic precision 90 %; sensitivity and specificity of about 90 % Able to distinguish current AD from controls with precision of 77 %
Casanova et al. 2016 [55]	Identical to Mapstone et al. [63]	BLSA cohort: AD (93) Control (99) AGES-RS cohort: AD (100) Control (100)	In fasting serum: 187 metabolites probed including 10 lipid panel previously identified by Mapstone et al. [63]	Larger-scale attempt at validating the 10 lipid panel from Mapstone et al. [63] in serum samples collected after overnight fast BLSA cohort: diagnostic precision for distinguishing MCI-to-AD converters from controls was 64 %, sensitivity 51 % and specificity 65 % AGES-RS cohort: diagnostic precision for distinguishing MCI-to-AD converters from controls was 39 %, sensitivity 47 %, specificity 36 % Across both cohorts, able to distinguish current AD from controls with precision of 48–58 % Other metabolites flagged in wider screen as being useful discriminators in BLSA cohort were not replicated in AGES-RS cohort
Jaeger et al. 2016 [61]	Antibody microarray	AD (47) Control (52) svPPA (92)	600 secreted cell signalling proteins probed	3 groups of proteins identified that discriminate AD from control and from svPPA: 'complement', 'apoptosis' and 'regulation of growth', including a new TGFB/GDP/BMP pathway which was then investigated in post-mortem human brain homogenates and in murine hippocampal culture models 39 proteins identified that are over- or under-expressed in both AD and svPPA

Aβ amyloid- β , *AC* affinity chromatography, *AD* Alzheimer's disease, *ADMI* Alzheimer's Disease Neuroimaging Initiative, *AGES-RS* Age, Gene/Environmental Susceptibility – Reykjavik Study, *AIBL* Australian Imaging, Biomarkers and Lifestyle study, *APOE* apolipoprotein E, *BLSA* Baltimore Longitudinal Study of Ageing, *BNP* brain natriuretic peptide, *CDR* Clinical Disease Rating scale as per the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association) 1984 criteria for Alzheimer's disease, *CEA* carcinoembryonic antigen, *CRP* C-reactive protein, *CSF* cerebrospinal fluid, *EGF* epidermal growth factor, *EGFR* epidermal growth factor receptor, *ELISA* enzyme-linked immunosorbent assay, *IGFBP2* insulin-like growth factor binding protein 2, *IL-17* interleukin-17, *LC* liquid chromatography, *MCI* mild cognitive impairment, *MIP-1 δ* macrophage inflammatory protein-1 δ , *MS* mass spectrometry, *PDGF-BB* platelet-derived growth factor BB, *Penn* University of Pennsylvania cohort, *PPY* pancreatic polypeptide, *SDS-PAGE* sodium dodecyl sulphate polyacrylamide gel electrophoresis, *svPPA* semantic variant primary progressive aphasia, *TGFB/GDP/BMP* transforming growth factor- β /growth differentiation factor/bone morphogenetic protein, *t-tau* total tau, *VCAM* vascular cell adhesion molecule, *WB* Western blot, *WU* Washington University cohort

of AD. A selection of some notable studies is provided in Table 2. The earliest of these studies, by Ray et al. [52] in 2007, used a sandwich ELISA immunoassay platform and identified an 18-analyte panel of proteins that segregated AD from controls. However, in an attempt at replication in another cohort (ADNI), by using seven of the analytes that gave a combined diagnostic accuracy of 90 % in the Ray et al. [52] study, 61 % diagnostic accuracy was achieved, and the incorporation of a different 89-analyte panel increased this to 70 % [53]. These results, however, have been difficult to replicate [54, 55]. Doecke et al. [56] cross-validated panels of biomarkers obtained from AIBL (Australian Imaging, Biomarkers and Lifestyle study) against ADNI, and found just two biomarkers that had individual effect sizes greater than 1.5 that were common to both cohorts: insulin-like growth factor binding protein 2 and pancreatic polypeptide. However, when a multivariate model using a panel of eight plasma biomarkers was added to the predictive capacity of a model based on age, sex and *APOE* genotype, the biomarker panel was only able to increase sensitivity and specificity from 77 to 83 %. This emphasises the importance of assessing how much actual additional predictive information is provided by these tests, as it ultimately relates to the cost-benefit analyses that will determine their ability to translate into more general research or clinical settings.

Other multiplexing techniques have used mass spectroscopy, preceded by either liquid chromatography or differential matrix or surface adsorption to enrich samples for proteins at low concentration. While this type of approach does not rely on the availability of specific antibodies to the analytes of interest, it is this very point that makes the data noisy. Zhang et al. [57] piloted this approach by identifying four proteins in AD versus control sera, using mass spectroscopy, which was then cross-validated using immunoassays (ELISA and Western blot). Similar methods have been employed to compare signatures of metabolites in CSF and plasma of controls, MCI and AD patients [58]. A newer method is the use of aptamer-based microarrays, which use oligonucleotides that function with high specificity, almost like ‘chemical antibodies’, but are more thermally stable and might therefore be more clinically translatable [59].

Multiplexing provides clear advantages by allowing large numbers of candidate biomarkers to be screened, provided that these replicate well across cross-sectional and longitudinal cohorts. Although to date replication has largely been lacking, the primary ‘hits’ obtained so far have often segregated into classes of proteins identified from other realms of biology, for example from the ‘inflammatory cascade’, ‘lipid metabolism’, ‘complement’ and other groups. However, it is uncertain to what extent one can extrapolate the role of these proteins from blood to

a distant underlying pathology in the CNS. Data-driven approaches also have other disadvantages. Firstly, to quote Lopez et al. [60], “Given a sufficiently large pool of potential proteins and peptides, one is almost certain to identify a pattern that discriminates between persons with and without disease within any given data set”. This is the age-old problem of multivariate analysis, which can be mitigated to some extent by statistical rigour, but ultimately requires replication in independent cohorts. Secondly, biomarkers may be able to answer more powerful questions if their relationship to pathology, and indeed to factors such as healthy aging or other dementia pathologies, is known. We can begin to derive such knowledge by integrating diverse research tools such as genomics and transcriptomics with proteomics. A recent example is the work of Jaeger et al. [61] who used an in-house immune microarray to probe a library of 600 secreted signaling proteins in plasma from AD patients, semantic dementia patients and healthy controls. They identified protein clusters that map to ‘complement’, ‘apoptosis’ and ‘regulation of growth’, many of which were hits on previous multiplex analyses, but a novel pathway, the TGF β /GDF/BMP (transforming growth factor- β /growth differentiation factor/bone morphogenetic protein) cluster, was identified. The potential relevance of this pathway was supported through the demonstration of a large number of single nucleotide polymorphisms at the gene level in AD patients, and correlation with lower GDF3 protein levels in post-mortem cortical extracts from AD patients. Whilst replication in other cohorts and validation using more conventional immunoassays such as ELISA will be required, the identification of this pathway illustrates that an integrated approach may prove to be a way of discovering new biomarkers and elucidating their function, with the ultimate aim of identifying therapeutic targets.

5 Moving Forward

Despite the inherent problems in developing blood-based biomarkers that accurately reflect brain biochemistry, ever more sensitive instruments and unbiased methodologies to screen large numbers of proteins concurrently mean that there is now a very real prospect of clinically useful blood-based biomarkers for AD. Blood measures of tau and of NFL are currently leading blood-based biomarker candidates; further work is required to understand what role they may play as diagnostic, prognostic or outcome measures in AD.

Compliance with Ethical Standards

Conflict of interest Ashvini Keshavan and Amanda Heslegrave have nothing to declare. Henrik Zetterberg is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based

platform company at the University of Gothenburg, Sweden. Jonathan M. Schott has funding from Alzheimer's Research UK, the Medical Research Council, AVID Radiopharmaceuticals, the Wolfson Foundation, the Brain Research Trust and EU Horizon 20:20 but none has influenced the preparation of this paper.

Funding No funding was received for the preparation of this paper.

References

- Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol.* 2014;13(6):614–29.
- Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. *Ann Neurol.* 1995;38:643–8.
- Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. *J Neurochem.* 1993;61:1828–34.
- Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neurosci Lett.* 2000;285:49–52.
- Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. *JAMA.* 2003;289:2094–103.
- Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid [beta]-amyloid 42 and tau proteins as biomarker changes in the brain. *Arch Neurol.* 2009;66:382–9.
- Shaw LM, Vanderstichele H, Knapik-Czajka M, Alzheimer's Disease Neuroimaging Initiative, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol.* 2009;65:403–13.
- Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of cerebrospinal fluid markers of Alzheimer pathology in subjects with subjective cognitive impairment and mild cognitive impairment. The DeSCRIPA study. *Lancet Neurol.* 2009;8:619–27.
- Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA.* 2009;302:385–93.
- Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):257–62.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):263–9.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):270–9.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):280–92.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: neurogranin (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-neurogranin-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. MCI-AD vs MCI-stable: neurogranin (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/mci-ad-vs-mci-stable-neurogranin-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: hFABP (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-hfabp-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: NSE (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-nse-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: NFL (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-nfl-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: YKL-40 (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-ykl-40-csf>. Accessed 30 May 2016.
- Alzforum. Alzbiomarker [web-based resource]. Alzheimer's disease vs control: VLP-1 (CSF). <http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-vlp-1-csf>. Accessed 30 May 2016.
- Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. *Neurology.* 2016;86(9):829–35.
- Paterson RW, Toombs J, Slattery CF, et al. Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. *J Neurol.* 2015;262(12):2722–30.
- Kroksveen AC, Opsahl JA, Aye TT, et al. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. *J Proteomics.* 2011;74(4):371–88.
- Wildsmith KR, Schauer SP, Smith AM, et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. *Mol Neurodegener.* 2014;9:22.
- Heywood WE, Galimberti D, Bliss E, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Mol Neurodegener.* 2015;10:64.
- Toledo JB, Vanderstichele H, Figurski M, et al. Alzheimer's disease neuroimaging initiative: factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. *Acta Neuropathol.* 2011;122:401–13.
- Huang Y, Potter R, Sigurdson W, et al. Beta-amyloid dynamics in human plasma. *Arch Neurol.* 2012;69:1591–7.
- Le Bastard N, Aerts L, Leurs J, et al. No correlation between time-linked plasma and CSF Abeta levels. *Neurochem Int.* 2009;55:820–825.
- Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta[40] and Abeta[42] as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. *Neurobiol Aging.* 2010;31:357–67.
- Devanand DP, Schupf N, Stern Y, et al. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. *Neurology.* 2011;77:125–131.
- Lui JK, Laws SM, Li QX, AIBL Research Group, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. *J Alzheimers Dis.* 2010;20:1233–42.
- Figurski MJ, Waligorska T, Toledo J, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. *Alzheimers Dement.* 2012;8:250–60.

33. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol.* 2016;15(7):673–84.
34. Alzforum. Alzbiomarker [web-based resource]. <http://www.alzforum.org/alzbiomarker>. Accessed 9 May 2016.
35. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Tau is reduced in AD plasma and validation of employed ELISA methods. *Am J Neurodegener Dis.* 2012;1(1):99–106.
36. Wang T, Xiao S, Liu Y, et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. *Int J Geriatr Psychiatry.* 2014;29(7):713–9.
37. Chiu MJ, Yang SY, Horng HE, et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. *ACS Chem Neurosci.* 2013;4(12):1530–6.
38. Chiu MJ, Chen YF, Chen TF, et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. *Hum Brain Mapp.* 2014;35(7):3132–42.
39. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease. *Alzheimers Res Ther.* 2013;5(2):9.
40. Wilson DH, Rissin DM, Kan CW, et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. *J Lab Autom.* 2016;21(4):533–47.
41. Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β -amyloid in Alzheimer's disease and vascular disease. *Sci Reports* 2016;6:26801. doi:10.1038/srep26801.
42. Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population based elderly cohort. *Neurology.* 2016. doi:10.1016/j.jalz.2016.06.001.
43. Neselius S, Zetterberg H, Blennow K, et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. *Brain Inj.* 2013;27(4):425–33.
44. de Jong D, Jansen RW, Pijnenburg YA, et al. CSF neurofilament proteins in the differential diagnosis of dementia. *J Neurol Neurosurg Psychiatry.* 2007;78(9):936–8.
45. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. *Ann Neurol.* 2014;75(1):116–26.
46. Wilke C, Preische O, Deuschle C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. *J Neurol Neurosurg Psychiatry.* 2016. doi:10.1136/jnnp-2015-312972.
47. Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. *Neurology.* 2016;87(13):1329–36.
48. Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. *Neuron.* 2016;91:1–11.
49. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. *Clin Chem Lab Med.* 2016;54(10):1655–61. doi:10.1515/cclm-2015-1195.
50. Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. *EBioMedicine.* 2015;22(3):135–40.
51. O'Bryant SE, Gupta V, Henriksen K, STAR-B and BBBIG working groups, et al. Guidelines for the standardization of pre-analytic variables for blood-based biomarker studies in Alzheimer's disease research. *Alzheimers Dement.* 2015;11(5):549–60.
52. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. *Nat Med.* 2007;13(11):1359–62.
53. Soares HD, Chen Y, Sabbagh M, et al. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. *Ann N Y Acad Sci.* 2009;1180:56–67.
54. Björkqvist M, Ohlsson M, Minthon L, et al. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. *PLoS One.* 2012;7(1):e29868.
55. Casanova R, Varma S, Simpson B, et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. *Alzheimers Dement.* 2016;12(7):815–22.
56. Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. *Arch Neurol.* 2012;69(10):1318–1325.
57. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. *Proteomics.* 2004;4(1):244–56.
58. Trushina E, Dutta T, Persson XT, et al. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. *PLoS One.* 2013;8(5):e63644.
59. Sattler M, Kiddle SJ, Newhouse S, et al. AddNeuroMed Consortium. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. *Alzheimers Dement.* 2014;10(6):724–34.
60. Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. *Clin Chem.* 2005;51:1946–54.
61. Jaeger PA, Lucin KM, Britschgi M, et al. Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. *Mol Neurodegener.* 2016;11:31. doi:10.1186/s13024-016-0095-2.
62. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology.* 2012;79:897–905.
63. Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory impairment in older adults. *Nat Med.* 2014;20:415–8.